AJP - Gastrointestinal and Liver Physiology, Vol 259, Issue 3 355-G363, Copyright © 1990 by American Physiological Society

ARTICLES

Gastrointestinal motor effects of erythromycin

M. F. Otterson and S. K. Sarna
Department of Surgery, Medical College of Wisconsin, Milwaukee.

We studied the small intestinal motor effects of oral and intravenous (iv) erythromycin in 10 conscious dogs. After control recordings with placebo, oral or iv erythromycin was given at 40% of the migrating motor complex (MMC) cycle. Recordings were made after administration until normal contractile activity had returned or 12 h postdrug administration. Low doses initiated a premature MMC. High doses, however, prolonged the MMC cycle length. Erythromycin reduced the MMC propagation velocity at all doses. Both oral and iv erythromycin induced amyogenesia. During this pattern, electrical control activity was obliterated in the proximal and destabilized in the distal small intestine. Erythromycin also increased the incidence of retrograde giant contractions (RGCs) and vomiting. These effects occurred within the first 2 h after oral and within the first 30 min after iv administration. The incidence of giant migrating contractions (GMCs) increased significantly from 5 to 12 h but not from 0 to 5 h after administration. The distance of origination of GMCs from the ileocolonic junction was significantly increased from 5 to 12 h. The amplitude ratio, duration, and velocity of migration of GMCs induced after erythromycin were similar to control values. Clusters of coordinated antral and duodenal contractions also occurred early after administration. Our findings suggest that erythromycin has multiple motor effects on the stomach and small intestine. Diarrhea, abdominal cramping, and vomiting associated with erythromycin may be related to increased incidence of GMCs and RGCs. Erythromycin has a biphasic effect on MMC cycle length, initiating premature MMCs at low doses and prolonging their cycle length at higher doses.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				P C Ng, K W So, K S C Fung, C H Lee, T F Fok, E Wong, W Wong, K L Cheung, and A F B Cheng Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2001; 84(3): 177F - 182. [Abstract] [Full Text]

				B. J Stenson, L. Middlemist, and A. J Lyon Influence of erythromycin on establishment of feeding in preterm infants: observations from a randomised controlled trial Arch. Dis. Child. Fetal Neonatal Ed., November 1, 1998; 79(3): 212F - 214. [Abstract] [Full Text]

				M.-G. Choi, M. Camilleri, D. D. Burton, S. Johnson, and A. Edmonds Dose-Related Effects of N-Demethyl-N-Isopropyl-8,9-anhydroerythromycin A 6,9-hemiacetal on Gastric Emptying of Solids in Healthy Human Volunteers J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 37 - 40. [Abstract] [Full Text]

				C. Mathis and C. H. Malbert Erythromycin gastrokinetic activity is partially vagally mediated Am J Physiol Gastrointest Liver Physiol, January 1, 1998; 274(1): G80 - G86. [Abstract] [Full Text] [PDF]